中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 3
Mar.  2020
Turn off MathJax
Article Contents

Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells

DOI: 10.3969/j.issn.1001-5256.2020.03.024
Research funding:

 

  • Received Date: 2019-10-06
  • Published Date: 2020-03-20
  • Objective To investigate the effect of proteasome subunit beta type 4( PSMB4) on the proliferation and viability of human liver cancer SMMC7721 cells and its possible mechanisms. Methods The specific short-hairpin RNA( shRNA) technique was used to construct SMMC7721 cells with knockdown expression of PSMB4,and these cells were selected as experimental group. MTT assay and colony-forming assay were used to observe the change in cell proliferation,flow cytometry was used to measure the change in cell apoptosis rate,and Western blot was used to measure the change in the expression of related proteins. The independent samples t-test was used for comparison of continuous data between two groups. Results SMMC7721 cells with knockdown expression of PSMB4 were successfully constructed( shRNA1: t = 22. 67,P < 0. 0001; shRNA2: t = 30. 88,P < 0. 0001; shRNA3: t = 67. 82,P < 0. 0001). The MTT assay showed that the experimental group had a significantly lower OD490 value than the control group on day 4( 0. 4770 ± 0. 0135 vs 0. 3237 ± 0. 0127,t =8. 286,P = 0. 0012) and day 5( 0. 5893 ± 0. 0088 vs 0. 3847 ± 0. 0090,t = 16. 220,P < 0. 0001). The colony-forming assay showed a significant reduction in the number of cell colonies in the experimental group. Flow cytometry showed that compared with the control group,the experimental group had significantly higher early apoptosis rate( 5. 5570% ± 0. 2589% vs 3. 8870% ± 0. 3324%,t = 3. 964,P = 0. 0166),late apoptosis rate( 12. 6300% ± 0. 4198% vs 5. 3100% ± 0. 3062%,t = 14. 080,P = 0. 0001),and total apoptosis rate( 18. 1800% ± 0. 6785%vs 9. 1970% ± 0. 6313%,t = 9. 967,P = 0. 0006),as well as a significant reduction in the protein expression of nuclear factor-kappa B p65( 0. 8015 ±0. 0120 vs 0. 2841 ±0. 0110,t =31. 830,P <0. 0001) and a significant increase in the protein expression of nuclear factor-kappa B inhibitory protein α( 0. 4816 ± 0. 0112 vs 0. 6583 ± 0. 0142,t = 9. 774,P = 0. 0006). Conclusion Knockdown of PSMB4 expression may reduce the proliferation and viability of liver cancer SMMC7721 cells by inhibiting the NF-κB signaling pathway.

     

  • loading
  • [1] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
    [2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [3] THOMAS MB,JAFFE D,CHOTI MM,et al. Hepatocellular carcinoma:Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting[J]. J Clin Oncol,2010,28(25):3994-4005.
    [4] JANG HH. Regulation of protein degradation by proteasomes in cancer[J]. J Cancer Prev,2018,23(4):153-161.
    [5] CHENG YC,TSAI WC,SUNG YC,et al. Interference with PSMB4expression exerts an anti-tumor effect by decreasing the invasion and proliferation of human glioblastoma cells[J]. Cell Physiol Biochem,2018,45(2):819-831.
    [6] DANTUMA NP,BOTT LC. The ubiquitin-proteasome system in neurodegenerative diseases:Precipitating factor,yet part of the solution[J]. Front Mol Neurosci,2014,7:70.
    [7] MEARINI G,SCHLOSSAREK S,WILLIS MS,et al. The ubiquitin-proteasome system in cardiac dysfunction[J]. Biochim Biophys Acta,2008,1782(12):749-763.
    [8] CSIZMAR CM,KIM DH,SACHS Z. The role of the proteasome in AML[J]. Blood Cancer J,2016,6(12):e503.
    [9] WANG CY,LI CY,HSU HP,et al. PSMB5 plays a dual role in cancer development and immunosuppression[J]. Am J Cancer Res,2017,7(11):2103-2120.
    [10] TAN S,LI H,ZHANG W,et al. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression[J]. Oncogene,2018,37(35):4887-4900.
    [11] AUGELLO G,MODICA M,AZZOLINA A,et al. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238(ixazomib)in hepatocellular carcinoma cells[J].Cell Death Dis,2018,9(2):28.
    [12] VANDEWYNCKEL YP,COUCKE C,LAUKENS D,et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma[J]. Oncotarget,2016,7(23):34988-35000.
    [13] LEE KM,LEE J,PARK CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type4[J]. Biochem Biophys Res Commun,2012,427(3):618-622.
    [14] WANG H,HE Z,XIA L,et al. PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis[J]. Oncol Rep,2018,40(4):2343-2352.
    [15] BU R,HUSSAIN AR,AL-OBAISI KA,et al. Bortezomib inhibits proteasomal degradation of IκBαand induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2014,55(2):415-424.
    [16] ZHENG P,GUO H,LI G,et al. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling[J]. Biochem Biophys Res Commun,2015,458(2):328-333.
    [17] LIU R,LU S,DENG Y,et al. PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis[J].Arch Gynecol Obstet,2016,293(6):1297-1307.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (924) PDF downloads(201) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return